Browsing Tag
icotrokinra
4 posts
Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis?
Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.
Johnson & Johnson’s icotrokinra demonstrates superiority in plaque psoriasis trials, setting stage for market disruption
New clinical trial data from Johnson & Johnson suggests that icotrokinra results could mark a major shift in…